A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC ZRC ‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

导出原文传递

翻译打印收藏纠错

作者： Jani Rajendrakumar H. ^[1] ; Gupta Rajiv ^[2] ; Bhatia Girish ^[3] ; Rathi Gaurav ^[4] ; Ashok Kumar Patnala ^[5] ; Sharma Reena ^[6] ; Kumar Uma ^[7] ; Gauri Liyakat A. ^[8] ; Jadhav Praveen ^[9] ; Bartakke Girishchandra ^[10] ; Haridas Vikram ^[11] ; Jain Dinesh ^[12] ; Mendiratta Sanjeev K.

作者单位： Clinical R & DCadila Healthcare LimitedAhmedabad,India ^[1] Omkar Heart Institute & Nursing Home & Rheumatology ClinicNasik,India ^[2] DMC & HospitalLudhiana,India ^[3] Department of OrthopedicsUnit‐2 King George HospitalVisakhapatnam,India ^[4] SP Medical College & Associated Group of HospitalsBikaner,India ^[5] B J Medical College and Sassoon General HospitalPune,India ^[6] Malpani Multispecialty HospitalJaipur,India ^[7] Medipoint Hospital Pvt. Ltd.Pune,India ^[8] Sushruta Multispecialty Hospital and Research Centre Pvt. Ltd.Vidyanagar, Hubli,India ^[9] Shalby HospitalAhmedabad,India ^[10] Clinical Immunology and Rheumatology ServiceAIIMSNew Delhi,India ^[11] Rathi Orthopaedic and Research CentreAhmedabad,India ^[12]

关键词 adalimumab biosimilar Exemptia Humira rheumatoid arthritis Zydus

发布时间 2020-03-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交